Sumitovant Biopharma Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sumitovant Biopharma Ltd. - overview
Established
2019
Location
London, -, UK
Primary Industry
Pharmaceuticals
About
Founded in 2019 and based in London, UK, Sumitovant Biopharma Ltd. is the holding company of Sumitovant Biopharma, Inc. , which focuses on developing innovative gene therapies for cystic fibrosis. The company manages the five spinoffs from Roivant Sciences, including Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences.
Current Investors
Sumitomo Pharma
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Aesthetic Medicine, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Total Amount Raised
Subscriber access only
Sumitovant Biopharma Ltd. - timeline of key events
Sumitovant Biopharma Ltd. - financials
| Fiscal Year Ended | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 12,989,685 | 21,729,629 | 28,187,372 | 5,360,570 | 23,502,972 | 10,864,577 | 15,796,618 | - | - | - |
| % Revenue Growth (YoY) | - | 67.3% | 29.7% | (81.0%) | 338.4% | (53.8%) | 45.4% | - | - | - |
| EBITDA (USD) | 139,349 | 352,119 | 199,056 | 175,555 | 211,692 | 733,597 | 4,934,823 | - | - | - |
| Operating Income (USD) | 73,333 | 247,170 | 96,223 | 58,966 | 96,368 | 138,817 | 4,876,450 | - | - | - |
| Operating Margin | 0.6% | 1.1% | 0.3% | 1.1% | 0.4% | 1.3% | 30.9% | - | - | - |
| % EBITDA Margin | 1.1% | 1.6% | 0.7% | 3.3% | 0.9% | 6.8% | 31.2% | - | - | - |
| NET Income (USD) | 19,968 | 27,767 | (91,722) | (289,892) | (280,927) | (203,059) | 6,089,303 | - | - | - |
| % Net Margin | 0.2% | 0.1% | (0.3%) | (5.4%) | (1.2%) | (1.9%) | 38.5% | - | - | - |
Sumitovant Biopharma Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Public to Private | Completed | Myovant Sciences Ltd. | - | ||||||||
| LP Direct | Completed | Sumitovant Biopharma Ltd. | - |
Displaying 1 - 2 of 2
Sumitovant Biopharma Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.